25/10/2010
Afghanistan
New bivalent polio vaccine playing key role in global polio eradication
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3) vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.
For details, please go to:
http://www.thelancet.com
Related News
11/06/2024
11 June 2024
06/06/2024
Advocating for a Polio-Free Future for Every Child
31/05/2024
Countries convening at this week’s World Health Assembly discuss a range of public health topics – but why does this matter for polio?
14/05/2024
After a thorough evaluation, an independent Polio Outbreak Response Assessment Team (OBRA), has concluded that there is no evidence of ongoing wild polio transmission in Mozambique and Malawi
